Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial
Importance Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high
burden for patients and limited existing therapeutic options. Objective To evaluate the
efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits
interleukin 17A and 17F in individuals with moderate to severe HS. Design, Setting, and
Participants This phase 2, double-blind, placebo-controlled randomized clinical trial with an
active reference arm was performed from September 22, 2017, to February 21, 2019. The …
burden for patients and limited existing therapeutic options. Objective To evaluate the
efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits
interleukin 17A and 17F in individuals with moderate to severe HS. Design, Setting, and
Participants This phase 2, double-blind, placebo-controlled randomized clinical trial with an
active reference arm was performed from September 22, 2017, to February 21, 2019. The …